Skip to main content
OpenTrials
Completed

NCT Number: NCT01883193

Women First: Preconception Maternal Nutrition

Multi-country three-arm, individually randomized, non-masked, controlled trial to ascertain the benefits of ensuring optimal maternal nutrition before conception and providing an evidence base for programmatic priority directed to minimizing the risk of malnutrition in all females of reproductive age.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo

Loading trial locations.

About this study

The objective is to determine the benefits to the offspring of women in poor, food-insecure environments of commencing a daily comprehensive maternal nutrition supplement (with additional balanced calorie/protein supplement for underweight participants) ≥ 3 months prior to conception versus the benefits of commencing the same supplement at 12 weeks gestation and also to compare offspring outcomes with those of a control group which receives no supplement.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 16-35 years of age;
  • expectation to have first or further pregnancy without intent to utilize contraception
  • Hb >8 g/dL

Exclusion criteria

  • Nulliparous women who do not agree to hospital delivery (equipped for caesarian section) or/and do not have ready access to such a facility.

Treatment and study plan

Comprehensive Maternal Nutrition Intervention

Dietary Supplement

The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.

Other names: multi micronutrient (MMN) fortified lipid-based supplement, lipid-based nutrient supplement, LNS

Primary outcomes

  1. Neonatal linear growth

    Time frame: <24 hours of age

    Research assistants will obtain neonatal length measurement at <24 hours of age.

Secondary outcomes

  1. Length-for-age Z-scores

    Time frame: age 0.5, 1, 3, 6, 12, 18 and 24 months postnatal

    Research assistants will obtain infant anthropometry measurements, which include length, head circumference, triceps skin folds, Mid Upper Arm Circumference (MUAC), and weight, at age 0.5, 1, 3, 6, 12, 18 and 24 months of age. Length-for-age Z-scores will be compared for offspring of mothers randomized to the three intervention arms.

  2. Estimate fetal growth

    Time frame: 12 weeks gestation

    Ultrasound measurements will be undertaken at 12 weeks gestation with the goals of confirming gestational age and estimating fetal growth.

  3. Mean birth weight

    Time frame: at birth

    As a dichotomous variable, the cutoff of 2500 g does not have the power of the continuum of birth length, but is included because of the long history of use in determining which newborns are severely underweight and this association with impaired neonatal and long-term prognosis. The design of this study will allow distinction between pre-term birth (PTB) and growth retardation of the term infant (mature IUGR).

  4. Incidence of low birth weight (LBW) infants

    Time frame: at birth

    As a dichotomous variable, the cutoff of 2500 g does not have the power of the continuum of birth length, but is included because of the long history of use in determining which newborns are severely underweight and this association with impaired neonatal and long-term prognosis. The design of this study will allow distinction between pre-term birth (PTB) and growth retardation of the term infant (mature IUGR).

  5. Perinatal Mortality

    Time frame: From 20 weeks gestation through 1 month of age

    The outcome is to determine, in poor food insecure communities if a daily comprehensive maternal nutrition supplement starting ≥ 3 months preconception and continuing throughout pregnancy will reduce the incidence of offspring perinatal mortality (including still births), compared with that for offspring of mothers who commence the same supplement starting at 12-16 weeks gestation.

  6. Incidence of severe neonatal and infant infectious disease

    Time frame: birth to 6 months of age

    Outcome measure is number of acute visits / admissions to health center/hospital for severe infectious disease. This secondary outcome will provide insight into the importance of maternal and fetal nutrition in the early prenatal development of host-defense mechanisms and, through comparison with the prenatal and control Arms, on the importance of maternal nutrition throughout pregnancy. It is further intended to collect minor morbidity data.

  7. Epigenome (Maternal)

    Time frame: baseline, 12 and 34 weeks gestation, delivery, and 3 months postpartum (maternal); 2 weeks and 3 months of age (infant)

    To compare longitudinal changes between groups in the maternal epigenome (including blood, buccal swabs, and possibly other readily obtainable samples) at baseline, 12 weeks pregnancy (prior to initiation of LNS in Arm 2), 34 weeks pregnancy, and at 3 months postpartum. Also will collect placental, fetal and cord blood epigenome at delivery by group and infant epigenome at 3 months with fingerstick blood and buccal swabs.

  8. Epigenome (Infant)

    Time frame: 2 weeks and 3 months of age

    To compare longitudinal changes between groups in the maternal epigenome (including blood, buccal swabs, and possibly other readily obtainable samples) at baseline, 12 weeks pregnancy (prior to initiation of LNS in Arm 2), 34 weeks pregnancy, and at 3 months postpartum. Also will collect placental, fetal and cord blood epigenome at delivery by group and infant epigenome at 3 months with fingerstick blood and buccal swabs.

  9. Deep phenotyping of maternal metabolic and nutritional status

    Time frame: 12 and 34 weeks gestation, delivery, and 3 months postpartum

    The outcome represents deep phenotyping by measuring in maternal tissues: hormones, metabolites, measures of inflammation, oxidant stress and immune function/status, and nutrient biomarkers as possible indices of fundamental metabolic alterations resulting from improved long-term maternal nutrition in food insecure populations. Longitudinal blood samples will be collected from maternal participants in Arms 1 and 2 at baseline, 12 weeks gestation (prior to initiation of LNS in Arm 2), 34 weeks gestation, delivery and 3 months postpartum. Samples will also be collected from participants in Arm 3 at 34 weeks gestation and at 3 months postpartum.

  10. Microbiome (maternal)

    Time frame: 12 & 34 weeks gestation and delivery (maternal)

    Based on potential long-term effects on maternal nutritional and metabolic state from preconception intervention, we hypothesize that the gut microbiota will differ between the two intervention arms at the three proposed time points.

  11. Microbiome (infant)

    Time frame: 14 days and 3 months of age (infant)

    Based on potential long-term effects on maternal nutritional and metabolic state from preconception intervention, we hypothesize that the gut microbiota will differ between the two intervention arms at the three proposed time points.

  12. Composition of breast milk

    Time frame: 14 days postpartum

    We hypothesize that improved maternal nutrition at the time of greatest plasticity in early pregnancy will favorably influence maternal metabolic and nutritional status throughout pregnancy and thus potentially the composition of breast milk in terms of hormonal content, immune factors, cytokines, and gut growth factors.

  13. Neurodevelopment assessment

    Time frame: 24 mo age

    Offspring randomized to receive neurodevelopmental evaluation (BSID-III or InterNDA, 2:1 ratio) at 24 mo of age

  14. Gestational weight gain (GWG)

    Time frame: Enrollment to delivery

    Describe GWG and its associations with fetal growth and birth outcomes within each country by baseline maternal nutritional status (BMI) and the receipt of nutrition interventions. Evaluate how GWG might mediate the effects of maternal nutrition interventions.

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Collaborators

  • Aga Khan University
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Instituto de Nutricion de Centroamerica y Panama (INCAP)
  • Jawaharlal Nehru Medical College
  • Kinshasa School of Public Health
  • RTI International

Registry information

Acronym: WF

Important dates

Study start
2013
Primary completion
2017
Study completion
2019
First posted
Jun 21, 2013
Registry last updated
Jul 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.